Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Moderna, Inc.

Market Cap 24.52B 21.32B 19.61B 18.44B 34.57B 2,318B 34.96B 233B 90.41B 1,138B 92.03B 90.06B 3,938B P/E 2026 *
-7.15x
P/E 2027 * -13.1x
Enterprise Value 20.96B 18.22B 16.76B 15.77B 29.55B 1,981B 29.89B 199B 77.28B 973B 78.67B 76.99B 3,366B EV / Sales 2026 *
10x
EV / Sales 2027 * 8.86x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.20%
1 week+29.48%
Current month+30.96%
1 month+26.02%
3 months+15.93%
6 months+106.76%
Current year+109.56%
1 week 46.3
Extreme 46.3
62.3
1 month 43.9
Extreme 43.9
62.3
Current year 29.81
Extreme 29.81
62.3
1 year 22.28
Extreme 22.28
62.3
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 62 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
06-05Fiscal year

General Counsel

29,301 0.0074%
06-01Fiscal year

General Counsel

5,377 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
+11.55%+29.48%+137.69%-51.99% 21.98B
-1.11%-1.34%+16.31%-22.36% 62.54B
+0.96%-3.77%+55.85%+194.24% 55.22B
+2.78%+37.00%+37.00%+37.00% 40.9B
+0.51%+7.36%-55.34%-61.57% 35.99B
+1.56%-0.22%+51.61%-33.22% 28.88B
-0.76%-4.11%+38.99%+56.56% 19.93B
-2.03%+2.32%-6.79%+103.95% 16.95B
+2.32%+1.06%+52.60%+95.04% 15.87B
+1.13%-0.43%+63.81%+348.97% 13.05B
Average +0.56%+2.10%+39.17%+66.66% 31.13B
Weighted average by Cap. +0.54%+1.64%+33.64%+49.71%

Financials

2026 *2027 *
Net sales 2.09B 1.82B 1.67B 1.58B 2.95B 198B 2.99B 19.91B 7.72B 97.23B 7.86B 7.69B 336B 2.51B 2.18B 2.01B 1.89B 3.54B 237B 3.58B 23.88B 9.26B 117B 9.43B 9.23B 403B
Net income -3.4B -2.96B -2.72B -2.56B -4.8B -322B -4.85B -32.36B -12.55B -158B -12.77B -12.5B -547B -1.84B -1.6B -1.47B -1.38B -2.59B -174B -2.62B -17.49B -6.78B -85.42B -6.91B -6.76B -295B
Net Debt -3.56B -3.09B -2.85B -2.68B -5.02B -336B -5.07B -33.84B -13.12B -165B -13.36B -13.07B -572B -2.27B -1.98B -1.82B -1.71B -3.2B -215B -3.24B -21.61B -8.38B -106B -8.53B -8.35B -365B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
17/06/26 61.80 $ +11.55% 12,335,008
16/06/26 55.40 $ +6.27% 13,050,523
15/06/26 52.13 $ +4.45% 6,342,068
12/06/26 49.91 $ +0.54% 5,081,172
11/06/26 49.64 $ +7.94% 6,196,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
61.80USD
Average target price
43.30USD
Spread / Average Target
-29.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!